Patents Assigned to Juno Therapeutics, Inc.
-
Patent number: 12036241Abstract: Compounds that either produce a higher proportion or greater absolute number of phenotypically identified naive, stem cell memory, central memory T cells, adaptive NK cells, and type I NKT cells are identified. Compositions and methods for modulating immune cells including T, NK, and NKT cells for adoptive cell therapies, such as those providing improvements in one or more therapeutic outcomes, are provided.Type: GrantFiled: July 19, 2018Date of Patent: July 16, 2024Assignees: FATE THERAPEUTICS, INC., JUNO THERAPEUTICS, INC.Inventors: Jonathan Rosen, Eigen Peralta, Ian Hardy, Betsy D. Rezner, Christian Maine, Daniel Shoemaker, David Robbins, Lucas Thompson
-
Publication number: 20240226298Abstract: Provided are B cell-activating factor receptor (BAFF-R)-binding molecules, in particular, to human antibodies specific for BAFF-R, including antibody fragments. The present disclosure further relates to recombinant receptors, including chimeric antigen receptors (CARs) that contain such antibodies or fragments, and polynucleotides that encode the antibodies, antigen-binding fragments or receptors specific for BAFF-R. Also provided are CARs which contain extracellular binding domains that bind to BAFF-R and B-lymphocyte antigen CD19 (CD19), genetically engineered cells expressing such CARs, and uses thereof in adoptive cell therapy.Type: ApplicationFiled: December 12, 2023Publication date: July 11, 2024Applicant: Juno Therapeutics, Inc.Inventors: Ruth Amanda SALMON, Douglas JONES, Brian BELMONT, Madeline WILLIAMS, Rebekah TURK, Eric William JEFFERY, Andres ALVAREZ, Yue JIANG, Gabriela DIAZ, Thomas COX, Chia-Yung WU, Tiffany HUELAR, Jon JONES, Stephanie BUSCH, Cedric CLEYRAT
-
Patent number: 12031975Abstract: Provided are methods and articles of manufacture for use with cell therapy for the treatment of diseases or conditions, e.g., cancer, including for predicting likelihood of the subject responding to a therapy, such as a cell therapy, e.g., a chimeric antigen receptor (CAR) T cell therapy. In some aspects, the predicting is based on detecting certain biomarkers of immune cells associated with and/or that correlate with response following administration of the therapy. The methods generally involve detecting a marker by assaying a biological sample from a subject that is a candidate for treatment, optionally with a cell therapy, to determine if the subject is likely to respond to the therapy. The present disclosure also provides methods for treating a subject having a disease or condition, in some cases involving administration of the cell therapy, based on assessment the biomarker. Also provided herein are reagents and kits for performing the methods.Type: GrantFiled: October 31, 2018Date of Patent: July 9, 2024Assignee: Juno Therapeutics, Inc.Inventors: Trevor Do, Howard Stern, Christina Swanson
-
Publication number: 20240197871Abstract: Provided are methods, compositions, uses and articles of manufacture of combination therapies involving immunotherapies, such as adoptive cell therapy, e.g., T cell therapy, and the use of (S)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione, or an enantiomer or mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof, for treating subjects with disease and conditions such as certain B cell malignancies, and related methods, compositions, uses and articles of manufacture. The cells generally express recombinant receptors such as chimeric antigen receptors (CARs). In some embodiments, the disease or condition is a non-Hodgkin lymphoma (NHL), such as relapsed or refractory NHL or specific NHL subtype.Type: ApplicationFiled: March 29, 2022Publication date: June 20, 2024Applicant: Juno Therapeutics, Inc.Inventors: Nikolaus Sebastian TREDE, Tim PULHAM, Fan WU, Michael POURDEHNAD, Joseph Andrew DESTEFANO, Maria Soraya CARRANCIO ANTON, Tonia Jane BUCHHOLZ, Michael PORTS, Jim QIN, Ronald DUBOWY, Nicolas BRAND
-
Patent number: 12006356Abstract: Provided are CCT5-binding molecules, including anti-CCT5 antibodies and antigen-binding fragments thereof such as heavy chain variable (VH) regions and single-chain antibody fragments, and conjugates comprising the anti-CCT5 binding molecules such as immunoconjugates and antibody-drug conjugates, and chimeric receptors comprising the anti-CCT5 binding molecules such as chimeric antigen receptors (CARs). In some embodiments, the anti-CCT5 antibodies or antigen-binding fragments thereof specifically bind to CCT5. Also provided are genetically engineered cells expressing the CARs or CCT5-binding molecules and uses thereof such as in adoptive cell therapy.Type: GrantFiled: December 14, 2018Date of Patent: June 11, 2024Assignee: Juno Therapeutics, Inc.Inventors: Susan Byrne, Richard Sullivan, Francois Vigneault
-
Publication number: 20240181052Abstract: Provided herein are methods and uses of combination therapies involving a T cell therapy, e.g., a CAR T cell therapy, and a checkpoint inhibitor therapy, e.g. an anti-PD-1 antibody and/or an anti-LAG3 antibody, for treating subjects with cancers such as lymphomas, and related methods, uses, and articles of manufacture.Type: ApplicationFiled: March 29, 2022Publication date: June 6, 2024Applicant: Juno Therapeutics, Inc.Inventors: Nikolaus Sebastian TREDE, Satyendra SURYAWANSHI, Shruti AGRAWAL, Shivani SRIVASTAVA, Tim PULHAM, Joe DESTEFANO, Nicolas BRAND, Ronald DUBOWY
-
Publication number: 20240168012Abstract: The present disclosure relates to methods of determining potency of a therapeutic cell compositions in connection with cell therapy. The cells of the therapeutic cell composition can express recombinant receptors such as chimeric receptors, e.g., chimeric antigen receptors (CARs) or other transgenic receptors such as T cell receptors (TCRs). The methods provide an assay for identifying the potency, including relative potency, of a therapeutic cell composition.Type: ApplicationFiled: March 21, 2022Publication date: May 23, 2024Applicants: Juno Therapeutics, Inc., Juno Therapeutics, Inc.Inventor: Neil HAIG
-
Publication number: 20240158837Abstract: Provided herein are methods of identifying genomic region(s) predictive of an outcome of treatment with a cell therapy and/or of a phenotype of function of the cells. In some embodiments, the methods include epigenetic and/or epigenomic analyses of the cells in connection with methods for preparing engineered cells for cell therapy and/or predicting response to a cell therapy, e.g., engineered cells for cell therapy. In some embodiments, the methods include steps to assess, characterize and analyze changes or modifications in an epigenetic property of gene region or regions, such as chromatin accessibility, nucleosome occupancy, histone modification, spatial chromosomal conformation, transcription factor occupancy and/or DNA methylation. In some embodiments, the epigenetic and/or epigenomic analysis includes determining the epigenetic properties of a cell, e.g., an engineered cell for cell therapy.Type: ApplicationFiled: October 17, 2023Publication date: May 16, 2024Applicant: Juno Therapeutics, Inc.Inventors: Mark L. BONYHADI, David G. KUGLER, Timothy G. JOHNSTONE, Ronald James HAUSE, Jr., Lucas J. THOMPSON, Ryan P. LARSON
-
Publication number: 20240159743Abstract: Provided herein are methods for assessing cell surface glycans, e.g., N-glycans, by assessing a sample of released surface glycans, and determining the presence, absence, or level of glycans present in the sample. Also provided are methods of assaying and/or evaluating a cell composition by assessing the cell surface glycan profile of the cell composition and comparing the profile to a reference sample. Methods for manufacturing and/or culturing a plurality of cell compositions having consistent surface glycan expression with low variability are also provided.Type: ApplicationFiled: September 15, 2023Publication date: May 16, 2024Applicant: Juno Therapeutics, Inc.Inventors: Paul Ken KODAMA, Tom KOWSKI, Mirna MUJACIC, Kenneth Mayo PRENTICE
-
Publication number: 20240151713Abstract: Provided are methods and articles of manufacture for use with cell therapy for the treatment of diseases or conditions, e.g., cancer, including for predicting and treating a toxicity. In some embodiments, the toxicity is a neurotoxicity or cytokine release syndrome (CRS), such as a severe neurotoxicity or a severe CRS. The methods generally involve detecting a marker by assaying a biological sample from a subject that is a candidate for treatment, optionally with a cell therapy, to determine if the subject is at risk for developing the toxicity, such as neurotoxicity or CRS or severe neurotoxicity or severe CRS. In some embodiments, the methods and articles of manufacture further includes a regent for assaying the biological sample and instructions for determining the percentage or number of cells positive for the marker in the biological sample.Type: ApplicationFiled: July 5, 2023Publication date: May 9, 2024Applicant: Juno Therapeutics, Inc.Inventors: Nathan YEE, Chris Glen RAMSBORG, Tina ALBERTSON, Ryan LARSON, He LI
-
Publication number: 20240115612Abstract: Provided are adoptive cell therapy methods involving the administration of doses of cells for treating disease and conditions, including certain B cell malignancies. The cells generally express recombinant receptors such as chimeric antigen receptors (CARs). In some embodiments, the methods are for treating subjects with non-Hodgkin lymphoma (NHL). In some embodiments, the methods are for treating subjects with relapsed or refractory NHL. Also provided are articles of manufacture and prophylactic treatments in connection with adoptive therapy methods.Type: ApplicationFiled: November 15, 2023Publication date: April 11, 2024Applicant: Juno Therapeutics, Inc.Inventors: Tina ALBERTSON, Brian CHRISTIN, Jacob Randolph GARCIA, Christopher Glen RAMSBORG, Claire L. SUTHERLAND, Clinton WEBER, Rachel K. YOST, Mark J. GILBERT, He LI
-
Patent number: 11952408Abstract: Provided are binding molecules, such as TCRs or antigen binding fragments thereof and antibodies and antigen-binding fragments thereof, such as those that recognize or bind human papilloma virus (HPV) 16, including HPV 16 E6 and HPV 16 E7. Also provided are engineered cells containing such binding molecules, compositions containing the binding molecules or engineered cells, and methods of treatment, such as administration of the binding molecules, engineered cells, or compositions.Type: GrantFiled: September 28, 2018Date of Patent: April 9, 2024Assignees: Juno Therapeutics, Inc., Editas Medicine, Inc.Inventors: Cameron Brandt, Brian Belmont, Christopher Borges, Stephen Michael Burleigh, Alexandra Croft, Stephen Jacob Goldfless, David Jeffrey Huss, Yue Jiang, Timothy G. Johnstone, David Koppstein, Hieu Nguyen, Christopher Heath Nye, Haley Peper, Blythe D. Sather, Sonia Timberlake, Dean Y. Toy, Queenie Vong, Gordon Grant Welstead, James Sissons
-
Publication number: 20240108654Abstract: Provided herein are methods, compositions and uses involving T cell therapies, such as adoptive T cell therapy, and an inhibitor of a Diacylglycerol kinase (DGK). The provided methods, compositions and uses include those involving the administration or use of one or more DGK inhibitors (DGKi) in a combination therapy with a T cell therapy, such as a genetically engineered T cell therapy involving cells engineered with a recombinant receptor, such as chimeric antigen receptor (CAR) or T cell receptor (TCR).Type: ApplicationFiled: March 2, 2022Publication date: April 4, 2024Applicant: Juno Therapeutics, Inc.Inventors: David G. KUGLER, Jim QIN, Alison MAIER, Richard OLSON, Michael WICHROSKI, Upender VELAPARTHI, Chetan Padmakar DARNE, Bireshwar DASGUPTA, Denise Christine GRUNENFELDER, Jayakumar Sankara WARRIER, Hasibur RAHAMAN, Prasada Rao JALAGAM, Saumya ROY, Pallavur SIVAKUMAR
-
Patent number: 11944647Abstract: Provided are adoptive cell therapy methods involving the administration of doses of cells for treating disease and conditions, including certain B cell malignancies. The cells generally express recombinant receptors such as chimeric antigen receptors (CARs). In some embodiments, the methods are for treating subjects with non-Hodgkin lymphoma (NHL). In some embodiments, the methods are for treating subjects with relapsed or refractory NHL. Also provided are articles of manufacture and prophylactic treatments in connection with adoptive therapy methods.Type: GrantFiled: June 22, 2022Date of Patent: April 2, 2024Assignee: Juno Therapeutics, Inc.Inventors: Tina Albertson, Brian Christin, Jacob Randolph Garcia, Christopher Glen Ramsborg, Claire L. Sutherland, Clinton Weber, Rachel K. Yost, Mark J. Gilbert, He Li
-
Publication number: 20240103012Abstract: Provided are methods, kits and compositions related to toxicity associated with administration of cell therapy for the treatment of diseases or conditions, e.g., cancer, including methods for use in predicting and treating a toxicity. In some embodiments, the toxicity is a neurotoxicity or cytokine release syndrome (CRS), such as a severe neurotoxicity or a severe CRS. The methods generally involve detecting a parameter of a biomarker or individually a parameter of each biomarker in a panel of biomarkers, such as a concentration, amount or activity, and comparing the detected parameter to a reference value for the parameter to determine if the subject is at risk for developing the toxicity, such as neurotoxicity or CRS or severe neurotoxicity or severe CRS.Type: ApplicationFiled: September 27, 2023Publication date: March 28, 2024Applicants: Juno Therapeutics, Inc., Fred Hutchinson Cancer Research CenterInventors: He LI, Mark J. GILBERT, David MALONEY, Stanley R. RIDDELL, Cameron J. TURTLE
-
Publication number: 20240084253Abstract: Provided herein are methods for screening for one or more activity of a recombinant receptor, including recombinant receptors containing an extracellular antigen-binding domain and an intracellular signaling domain, such as a chimeric antigen receptor (CAR). The methods include assessing activity of a cell expressing the recombinant receptor based on a detectable expression of a reporter molecule that is responsive to a signal through the intracellular signaling region of the recombinant receptor. In some embodiments, the activity assessed is an antigen-dependent or an antigen-independent activity. In some embodiments, the methods can be used to screen a plurality of reporter cells each containing a nucleic acid molecule encoding a candidate recombinant receptor, e.g. CAR, and assessing such cells or plurality of cells for one or more property or activity. The methods can be high-throughput. Also provided are reporter cells, cell compositions, nucleic acids and kits for use in the methods.Type: ApplicationFiled: November 9, 2023Publication date: March 14, 2024Applicant: Juno Therapeutics, Inc.Inventors: Rupesh AMIN, Aye CHEN
-
Publication number: 20240076617Abstract: Provided herein are methods and compositions for generating engineered cells, such as cells expressing a recombinant receptor, including methods involving stimulation and/or engineering of an input composition having a defined ratio of naïve-like CD4+ T cells to naïve-like CD8+ T cells. In particular, the methods can be used to engineer T cells with genetically engineered receptors, such as genetically engineered antigen receptors such as engineered (recombinant) TCRs and chimeric antigen receptors (CARs), or other recombinant chimeric receptors. Features of the methods include producing a more consistent and/or predictable T cell product and/or a product with lower toxicity compared with other methods.Type: ApplicationFiled: November 10, 2023Publication date: March 7, 2024Applicant: Juno Therapeutics, Inc.Inventors: Mirna MUJACIC, Ayu RAHARDJO
-
Patent number: 11919970Abstract: Provided are ROR1 binding molecules, including anti-ROR1 antibodies, including antibody fragments such as variable heavy chain (VH) regions, single-chain fragments, and chimeric receptors including the antibodies, such as chimeric antigen receptors (CARs). In some embodiments, the antibodies specifically bind to ROR1. Among the antibodies are human antibodies, including those that compete for binding to ROR1 with reference antibodies, such as a non-human reference antibody. Also provided are genetically engineered cells expressing the chimeric receptors, and uses of the binding molecules and cells adoptive cell therapy.Type: GrantFiled: December 14, 2020Date of Patent: March 5, 2024Assignee: Juno Therapeutics, Inc.Inventors: Yan Chen, Steven M. Shamah, Csaba Pazmany, Jui Dutta-Simmons
-
Publication number: 20240066122Abstract: Provided are methods for multiple administrations of cells for adoptive cell therapy, and for administering cells to subjects having received prior administrations, and compositions and articles of manufacture for use in the methods. The cells generally express recombinant molecules such as recombinant receptors, e.g., chimeric antigen receptors (CARs) and/or other transgenic receptors. The methods can involve administering cells expressing a first or prior receptor(s) and cells expressing a second or subsequent receptor(s), the second or subsequent receptor(s) being distinct from the first, and which generally do not express the first receptor, and/or administering the cells expressing the second receptor to a subject having received the first administration.Type: ApplicationFiled: October 20, 2023Publication date: February 29, 2024Applicant: Juno Therapeutics, Inc.Inventor: Mark J. GILBERT
-
Publication number: 20240053250Abstract: Provided are methods for flow cytometry analysis, including the setting and use of static gating thresholds separating positive fluorescence from negative fluorescence for each fluorescence channel in the assay.Type: ApplicationFiled: December 15, 2021Publication date: February 15, 2024Applicant: Juno Therapeutics, Inc.Inventors: Rebecca BRUNETTE, Ryan P. LARSON, Kevin HAWKINS